mesalamine suppository
Selected indexed studies
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. (Gut, 2019) [PMID:31562236]
- [Ulcerative colitis]. (Praxis (Bern 1994), 2016) [PMID:27223413]
- Mesalamine-induced eosinophilic pleural effusion. (BMJ Case Rep, 2020) [PMID:32303527]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- [Ulcerative colitis]. (2016) pubmed
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. (2019) pubmed
- Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. (2016) pubmed
- Mesalamine-induced eosinophilic pleural effusion. (2020) pubmed
- pH and redox dual response nano-suppository for the treatment of ulcerative colitis. (2024) pubmed
- Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. (2010) pubmed
- Mesalamine delivery systems: do they really make much difference? (2005) pubmed
- Development and validation of an in vitro release test (IVRT) method for a locally acting mesalamine suppository. (2025) pubmed
- Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis. (2016) pubmed
- [Mesalazine-induced acute hepatitis]. (2015) pubmed